Xenon, a noble gas present in trace amounts in Earth's atmosphere, has been recognized as a potential anesthetic agent since the 1940s. Unlike nitrous oxide, xenon possesses many features of an ideal anesthetic, including rapid induction and emergence from anesthesia, hemodynamic stability, and neuroprotective properties. Xenon’s mechanism of action is thought to involve the inhibition of NMDA receptors through interaction with the glycine-binding site. However, xenon's clinical use remains limited due to its scarcity, high cost, and competition with industrial applications.
Effects of Xenon on Cerebral Perfusion and Neuroprotection
The effect of xenon on cerebral perfusion has yielded conflicting results in various animal models. A notable human study by Laitio and colleagues using 15O-H₂O positron emission tomography (PET) demonstrated that xenon reduces cerebral blood flow (CBF) in regions rich in neuronal cell bodies, such as the cortex, while increasing CBF in areas associated with axon projections and white matter tracts. Importantly, xenon’s reduction in CBF correlates with a corresponding decrease in cerebral metabolic rate of oxygen consumption (CMRO₂), maintaining the balance between cerebral oxygen supply and demand. This makes xenon a promising candidate for neuroprotection, particularly in settings where preserving metabolic balance is critical, such as neurosurgery or ischemic brain injury. Despite these benefits, the high cost and limited availability of xenon restrict its widespread clinical use.
| Agent | Effect on CBF and CMRO2 | Effect on autoregulation and CO2 reactivity |
|---|---|---|
| Volatile anesthetics as a class | Consistently suppress CMRO2; transcranial Doppler and gas diffusion studies show a dose-dependent rise in CBF, while human MRI suggests minimal change in global CBF | Flow-metabolism coupling is uncoupled; vasodilation occurs independently of anesthetic depth |
| Isoflurane | Suppresses CMRO2 with a dose-dependent rise in CBF as part of the class effect; a more potent cerebrovascular vasodilator than sevoflurane at MAC-equivalent doses | Autoregulation intact up to 1 MAC; above 1.5 MAC flow becomes pressure-passive; hypocapnia can restore autoregulation at higher doses |
| Desflurane | Shares the class effect of CMRO2 suppression with vasodilation | Autoregulation intact up to 1 MAC, pressure-passive above 1.5 MAC; hypercapnia further disrupts it |
| Sevoflurane | Conflicting findings — no change, increases, and decreases in CBF have all been reported depending on anesthetic depth and conditions | Narrows the plateau of the autoregulatory curve and blunts responses to both hypercapnia and hypocapnia |
| Nitrous oxide | As a MAC-sparing adjunct, CBF increases while CMRO2 may rise, fall, or stay unchanged; as a single agent, CBF increases with no change or a decrease in CMRO2 | Vascular autoregulation remains intact whether it is used alone or in combination |
| Xenon | Reduces CBF in regions rich in neuronal cell bodies such as the cortex and increases it in white matter tracts; the CBF reduction is matched by a fall in CMRO2 | — |
